Characteristics and data reporting of rare disease clinical trials:

Getting better but still room for improvement

Nina K. Mair¹, Jürgen Gottowik¹, Raul Rodriguez-Esteban¹ and Timothy J. Seabrook¹

¹ Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F.

Hoffmann-La Roche Ltd., Basel, Switzerland.

Correspondence:

Nina K. Mair, University of Zurich, Winterthurerstrasse 190, 8057 Zürich, Telephone: +41 76 21

07073, E-Mail: mair.nina@virology.uzh.ch.

Word counts for text and abstract: Text, 5071 words; Abstract, 348 words

Figure/table count: 3 figures; 3 tables, 1 supplementary table

Reference count: 39 references

ABSTRACT

Background

It is estimated that there are more than 7,000 rare diseases (RDs) worldwide, impacting the lives of approximately 400 million people and only 5% have an approved therapy. Facing special challenges, including patient scarceness, incomplete knowledge of the natural history and only few specialized clinical sites, clinical trials (CT) are limited, making the data from trials critical for research and clinical care. Despite the introduction of the U.S. Food and Drug Administration Amendment Act (FDAAA) in 2007 requiring certain CTs to post results on the registry ClinicalTrials.gov within 12 months following completion, compliance has been reportedly poor. Here, we describe general characteristics of RD CTs, identify trends, and evaluate result reporting practices under the FDAAA aiming to draw awareness to the problem of non-compliance.

Methods

CTs conducted between 2008 and 2015 were extracted from the public U.S. trial registry ClinicalTrials.gov using the text mining software I2E (Linguamatics). Disease names were matched with rare disease names from the Orphanet Rare Disease Ontology (ORDO, v2.5, Orphanet). Statistical analyses and data visualization were performed using GraphPad Prism 7 and R (v3.5). The Student's t-test was employed to calculate significance using p-value cutoffs of <0.05 or <0.001.

Results

We analyzed 1,056 RD CTs of which 55.7% were phase 2, 7.7% phase 2/3 and 36.7% phase 3 trials. The studies were mostly one- and two-armed experimental CTs with the majority (60.2%) being funded by industry. Cystic fibrosis and sickle cell disease represented the most frequently investigated diseases (25.0% and 16.5%). Industry-led phase 2 RD CTs were significantly ($p < 0.0001$) shorter than their equivalent led by academia/non-profit (22 vs. 33

months). Screening CTs completed before the end of 2015, we found that of the 725 analyzed studies, 55.2% predominantly phase 2 CTs, did not report results. Taking their potential applicability to the FDAAA into account, 25.2% industry-funded and 28.0% academia/non-profit-funded trials failed to disclose results on ClinicalTrials.gov.

Conclusion

RD CTs tend to be comparatively small, industry-funded studies focusing on genetic and neurologic conditions. Sponsor-related differences in study design, duration, and enrollment were observed. There are still substantial shortcomings when it comes to result publication.

Key words: ClinicalTrials.gov, rare disease, result publication, FDAAA

INTRODUCTION

In the U.S., rare diseases (RDs) are defined as those that affect fewer than 200,000 people; in Europe, the definition is based on a frequency of 1 in 2,000 or fewer people. It is estimated that there are more than 7,000 RDs which together affect the lives of approximately 400 million people worldwide¹, and only half of these are genetically characterized². The medical need is still high as only 5% of RDs currently have an approved therapy³. To promote research into these largely underappreciated orphan diseases, the U.S. Food and Drug Administration (FDA) introduced the Orphan Drug Act in 1983, which provides several incentives for the development of treatments⁴. Although this initiative has been very successful with 745 FDA approvals (428 in the last ten years), 99.9% of which have been submitted by industry, more therapies are needed⁵.

Clinical research in RDs faces challenges that typically have less impact on clinical trials (CTs) conducted in common diseases. These include patient scarcity, incomplete knowledge of the natural history of the disease, and the limited number of clinical sites that can treat these patients. This often results in a limited number of CTs in each RD, making the

data from trials critical to research and clinical care. Despite the introduction of the U.S. Food and Drug Administration Amendment Act (FDAAA) in 2007⁶ requiring CTs matching specific criteria to post results on ClinicalTrials.gov within 12 months following trial completion, compliance has been reportedly poor. This may directly impact patient care and therapy development⁷⁻⁹. The purpose of this report is to describe the overall landscape of rare disease clinical trials (RD CTs), identify trends, and assess the practice of result reporting after the implementation of the FDAAA to raise awareness of the problem of non-compliance.

METHODS

Data sources

Trial records with a clinical trial identifier (NCT number), a brief/official title and a study start and end date between 2008 and 2015 were extracted from the publicly accessible U.S. trial registry ClinicalTrials.gov using the text mining software I2E from Linguamatics. The glossary of common site terms, which can be found on ClinicalTrials.gov¹⁰, was used to determine if a CT was experimental, interventional, used an active comparator and other terms used in this paper.

Dataset development

In order to distinguish RD CTs from common disease CTs, ClinicalTrials.gov condition specifications were matched with RD names from the Orphanet Rare Disease Ontology (ORDO) version 2.5 provided by Orphanet. Trials studying (rare) malignancies and communicable diseases were excluded, as well as all studies in phases 1, 1/2 and 4, and those without a study phase. Oncology CTs were excluded as rare oncology diseases are often included amongst other more common cancers as part of basket trials and thus did not reflect

a RD CT. Infectious disease CTs included many HIV and hepatitis studies, which are not rare in much of the world and thus were excluded. Phase 1 studies comprise healthy subjects, not reflecting RD patient populations.

Studies starting before 2008 were excluded, due to the introduction of the FDAAA in 2007, as well as studies with a study status other than “completed”. Finally, studies involving incorrectly entered information into the “condition” field of the registry or studies that involved poisoning or envenomation were manually removed. To examine result reporting, we generated a second dataset including studies with an indicated completion date beyond 2015, to provide the responsible party with more than two years for the study results to be analyzed and entered on ClinicalTrials.gov at the time of our analysis.

To determine study location, all study locations in the contacts and locations section of each study’s ClinicalTrials.gov record were examined and counted. A site was counted every time it was mentioned by a CT. Therefore, a single study site was included multiple times if it hosted more than one CT during the time period examined.

To determine the sponsor, we extracted the responsible party as indicated on ClinicalTrials.gov and manually allocated CTs to “industry” or “academia/non-profit” according to the source of funding. “Industry” referred almost exclusively to registered for-profit companies, while publicly funded entities, such as universities, foundations, associations and non-profit organizations were allocated to “academia/non-profit”. One study in the final dataset of 1,056 studies could not be unambiguously allocated to a sponsor and was therefore excluded from the respective analyses.

Statistical analyses and data visualization

Statistical analyses and data visualization were performed using GraphPad Prism 7. Microsoft Excel was used for statistical calculations to analyze enrollment due to cell number

limitations in GraphPad Prism 7. For calculations of significance, Student's t-test was employed using p-value cut-offs of <0.05 or <0.001 to demonstrate significant results.

RESULTS

Design characteristics of rare disease clinical trials (RD CTs)

An overview of the workflow resulting in the final dataset comprising 1,056 RD CTs is shown in **Fig 1**. Examining the general characteristics of the studies (**Table 1**), we found that trials were equally distributed across all years from 2008 to 2015 ($12.5 \pm 1.8\%$ trials per

year).

Figure 1. Flowchart showing the dataset development including filtering steps carried out to select the datasets for analysis.

Study Start Year	n (%)	Study Phases	n (%)
2008	149 (14.1)	Phase 2	588 (55.7)
2009	138 (13.1)	Phase 2/3	81 (7.7)
2010	137 (13.0)	Phase 3	387 (36.7)
2011	146 (13.8)	Number of Arms	n (%)
2012	144 (13.6)	Phase 2	588 (55.7)
2013	130 (12.3)	1	200 (18.9)
2014	120 (11.4)	2	256 (24.2)
2015	92 (8.7)	3	76 (7.2)
Study Arm Type	n (%)	4	39 (3.7)
Phase 2	588 (55.7)	5	10 (0.9)
Active Comparator	102 (9.7)	6	3 (0.3)
Experimental	458 (43.4)	8	1 (0.1)
No Intervention	1 (0.1)	10	1 (0.1)
Other	14 (1.3)	22	1 (0.1)
N/A	13 (1.2)	N/A	1 (0.1)
Phase 2/Phase 3	81 (7.7)	Phase 2/3	81 (7.7)
Active Comparator	24 (2.3)	1	19 (1.8)
Experimental	55 (5.2)	2	50 (4.7)
Other	1 (0.1)	3	7 (0.7)
Placebo Comparator	1 (0.1)	4	5 (0.5)
Phase 3	387 (36.6)	Phase 3	387 (36.7)
Active Comparator	84 (8.0)	1	116 (11.0)
Experimental	292 (27.7)	2	215 (20.4)
Other	8 (0.8)	3	37 (3.5)
Placebo Comparator	1 (0.1)	4	12 (1.1)
N/A	2 (0.2)	5	2 (0.2)
		6	4 (0.4)
		7	1 (0.1)

Table 1. Characteristics of the 1056 completed Phase 2, 2/3 and 3 CTs registered at ClinicalTrials.gov. For each study arm type, the overall distribution of the evaluated CTs is highlighted in bold with the respective proportion of each study arm type listed below. The same applies to the table depicting the number of study arms.

More than half of the studies analyzed were in phase 2 (55.7%), followed phase 3 (36.7%) and 2/3 (7.7%). While phase 2 and phase 3 CTs showed a similar proportion of experimental

(77.9% and 75.5%) and active comparator (17.3% and 21.7%) study arm types, phase 2/3 CTs tended to include more active comparator studies (29.6%) with 67.9% of the studies being experimental. Here, 49.4% of all CTs are two-armed studies, followed by one-armed studies (31.7%). 60.2% CTs were industry-funded and 39.8% were academia/non-profit-funded. While phase 2 and phase 3 CTs were predominantly industry-sponsored, with 53.9% and 74.1%, respectively, academia/non-profit prevailed in phase 2/3 CTs (60.5%).

Disease categories

To generate a more comprehensive view of the RD CT landscape, we analyzed the disease areas addressed in this dataset. By leveraging the Orphanet Diseases 2.5 ontology, we were able to map all but one trial to specific conditions. Each CT could be allocated to up to seven diseases and each disease could be assigned to more than one category. The ten most common rare disease categories were genetic disease (19.4%), neurologic disease (12.3%), respiratory disease (8.2%), eye disease (6.4%), systemic or rheumatologic disease (5.9%), hematologic disease (5.4%), renal disease (5.0%), infertility (4.7%), skin disease (4.4%) and developmental defect (4.1%). These accounted for 75.8% of all diseases. In fact, 92.9% (n=971) of the RD CTs were mapped to at least one of the top 10 categories. In detail, 35.8% (n=378) of the studies were mapped to one top-ten category, 21.8% (n=230) were mapped to two and 20.5% (n=216) to three.

Furthermore, we found that the top ten diseases account for 86.2% of all CTs with cystic fibrosis (CF) accounting for 25.0%, followed by sickle cell disease (16.5%), hemophilia (8.7%), Fabry disease (6.3%), fragile X syndrome (6.1%), Huntington disease (5.7%), sarcoidosis (4.9%), systemic sclerosis (4.9%), Friedreich Ataxia (4.3%) and muscular dystrophies (primarily Duchenne, but also Becker and oculopharyngeal muscular dystrophy) (3.9%). To determine whether the ten most investigated diseases also reflect the leading

diseases in each category, the various conditions were analyzed based on their by the sponsor designated category. While, CF dominates the “rare” categories genetic diseases (15.7%), respiratory diseases (37.1%) and infertility (64.2%), sickle cell disease was found first in the categories systemic or rheumatologic disease (16.9%) and renal disease (20.0%). The three most researched conditions in other areas are hemophilia (29.3%) in hematologic disease, alopecia (24.2%) in skin disease, and amyotrophic lateral sclerosis (12.1%) in neurologic disease.

Compared to the entire corpus of 2,257,370 CTs entered in ClinicalTrials.gov, most studies in ClinicalTrials.gov investigated cancers and other neoplasms (13.8%), followed by general pathology (10.5%), nervous system diseases (9.2%), digestive system diseases (6.7%), heart and blood diseases (6.6%) and behaviors and mental disorders (6.5%). Thus, RD CTs represent a different spectrum of disease areas as compared to more common diseases. In summary, the majority of the investigated diseases in our dataset are rare genetic and neurologic conditions with CF and sickle cell disease being the most studies diseases.

Intervention type

Next, intervention types across study phases together with sponsors were analyzed (**Table 2**). Compared to ClinicalTrials.gov, where 45.6% (n=135,555) of all registered CTs involve drugs and biologicals as primary intervention type¹¹, drug interventions (including small molecules) constituted 78.5% (n=829) of the CTs in our dataset, followed by biologicals (13.1%, n=138).

In detail, 81.3% (n=257) of phase 2 RD CTs conducted by industry were found to involve drugs, followed by biologicals (14.2%, n=45) and devices (2.2%, n=7). Similarly, drugs and biologicals with 78.7% (n=214) and 5.9% (n=16) respectively, made up the majority of phase 2 CTs in the academia/non-profit sector. Notably, academia/non-profit-led trials tended to

investigate intervention types beyond drugs or biologicals, such as dietary supplements, devices or procedures. Phase 3 RD CTs were found to be almost exclusively industry-sponsored and investigate drugs (78.4%) or biologicals (20.9%). Academia/non-profit CTs focused on drugs (79.8%), but not on biologicals (1.0%). In summary, the majority of studies investigate drugs with the main sponsor being industry, whereas academia/non-profit-led trials tend to explore a broader range of intervention types.

Intervention Type per phase	Industry			Academia/Non-Profit		
	n (% per Phase)	n (% per Intervention Type)	n of CTs in this phase (%)	n (% per Phase)	n (% per Intervention Type)	n of CTs in this phase (%)
Phase 2	316 (53.7)			272 (46.3)		
Behavioral	0 (0.0)	0 (0.0)	0 (0.0)	5 (0.9)	5 (100.0)	5 (1.8)
Biological	45 (7.7)	45 (73.8)	45 (14.2)	16 (2.7)	16 (26.2)	16 (5.9)
Combination Product	1 (0.2)	1 (100.0)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)
Device	7 (1.2)	7 (53.8)	7 (2.2)	6 (1.0)	6 (46.2)	6 (2.2)
Dietary Supplement	1 (0.2)	1 (11.1)	1 (0.3)	8 (1.4)	8 (88.9)	8 (2.9)
Drug	257 (43.7)	257 (54.6)	257 (81.3)	214 (36.4)	214 (45.4)	214 (78.7)
Genetic	1 (0.2)	1 (50.0)	1 (0.3)	1 (0.2)	1 (50.0)	1 (0.4)
Other	1 (0.2)	1 (11.1)	1 (0.3)	8 (1.4)	8 (88.9)	8 (2.9)
Procedure	3 (0.5)	3 (20.0)	3 (0.9)	12 (2.0)	12 (80.0)	12 (4.4)
Radiation	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.3)	2 (100.0)	2 (0.7)
Phase 2/Phase 3	32 (39.5)			49 (60.5)		
Behavioral	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (100.0)	1 (2.0)
Biological	14 (17.3)	14 (87.5)	14 (43.8)	2 (2.5)	2 (12.5)	2 (4.1)
Device	1 (1.2)	1 (25.0)	1 (3.1)	3 (3.7)	3 (75.0)	3 (6.1)
Dietary Supplement	0 (0.0)	0 (0.0)	0 (0.0)	4 (4.9)	4 (100.0)	4 (8.2)
Drug	16 (19.8)	16 (30.2)	16 (50.0)	37 (45.7)	37 (69.8)	37 (75.5)
Other	1 (1.2)	1 (100.0)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)
Procedure	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.5)	2 (100.0)	2 (4.1)
Phase 3	287 (74.4)*			99 (25.6)*		
Behavioral	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.5)	2 (100.0)	2 (2.0)
Biological	60 (15.5)	60 (98.4)	60 (20.9)	1 (0.3)	1 (1.6)	1 (1.0)
Device	1 (0.3)	1 (25.0)	1 (0.3)	3 (0.8)	3 (75.0)	3 (3.0)
Dietary Supplement	1 (0.3)	1 (16.7)	1 (0.3)	5 (1.3)	5 (83.3)	5 (5.1)
Drug	225 (58.3)	225 (74.0)	225 (78.4)	79 (20.5)	79 (26.0)	79 (79.8)

Mair et al.

Characteristics and data reporting in rare disease clinical trials

Other	0 (0.0)	0 (0.0)	0 (0.0)	5 (1.3)	5 (100.0)	5 (5.1)
Procedure	0 (0.0)	0 (0.0)	0 (0.0)	4 (1.0)	4 (100.0)	4 (4.0)

Table 2. Intervention Type per Phase and Sponsor for 1055 completed phase 2, 2/3 and 3 CTs registered at ClinicalTrials.gov. One study was removed from the analysis since the sponsor could not be assigned unambiguously to any of the two categories.

Study location

The selection of investigational sites can be pivotal for enrollment and overall study success and their number varies considerably depending on the sponsor. Out of the 1,056 trials in our dataset, 632 (59.8%) entered at least one study site and, analyzing both sponsor categories separately, no significant difference was found. While 58.3% of all 635 CTs run by industry entered a study location, it was 62.1% of those run by academia/non-profit out of 420. One study could not be allocated to a sponsor and was therefore excluded leaving 1,055 trials for analysis. Although CTs from all around the world can be registered in ClinicalTrials.gov, we found that 44.3% (n=4,431) of the study sites were located in the U.S.. Here, the sum of counts by location does not equal the total CT number, as each location indicated by a study is counted and a single study may be counted more than once. Analyzing the number of sites by continent, the majority of sites are located in North America (48.5%, n=4,845) and Europe (33.9%, n=3,387), followed by Asia (11.4%, n=1,141), Central and South America (2.9%, n=286), Australia and Oceania (2.7%, n=269) and Africa (0.7%, n=72). The countries with the most study sites were the U.S. with 4,431 sites, Germany with 621 sites, France with 566 sites, Japan with 429 sites, Canada with 414 sites and the UK with 395 sites as well as Italy and Spain, with 326 and 251 sites, respectively. Approximately one third of RD CTs were run at a single site (34.7%, n=219), followed by 14.9% with up to five sites, 12.5% with up to ten sites and 9.7% with up to 15 sites. 4.6% and 5.4% of the studies had up to 15 and 25 study sites, respectively, and 1.6% indicated more than 100. The remaining 16.8% were scattered between 25 and 100 study sites. Moreover, industry-led trials significantly increased the number of study sites with ascending study phase. Accordingly, the mean location number

for industry in phases 2, 2/3 and 3 was 15.0 (median of 7.5), 23.0 (median of 18.0) and 32.7 (median of 23.5), while for academia the location numbers per phase were 3.1 (median of 1.0), 4.6 (median of 1.0) and 9.6 (median of 1.0). Compared to the entire trial corpus present on ClinicalTrials.gov, where 40% of the CTs indicated trial sites in the U.S. (35% U.S. only and 5% U.S. and non-U.S.), we found that RD CTs tend to be more often conducted in the U.S. (44.3%). In summary, the vast majority of trials entered into ClinicalTrials.gov are conducted in North America and Europe and despite a correlation between a higher numbers of trial sites and industry funding, single-site trials are the most common.

Participant enrollment

CT patient recruitment is critical and can be especially challenging in RD CTs due to patient scarceness and dispersion. The enrollment numbers in our dataset follow the typical trend observed in common diseases in that the number of participants increases with progressing study phase. Participant numbers were heterogeneous, as reflected by considerable standard deviation values. The median patient recruitment for industry CTs in phases 2, 2/3 and 3 was 40.0 (interquartile range (IQR), 21-76), 77.5 (IQR, 50-227), and 80.5 (IQR, 37-191), respectively, vs. 26.0 (IQR, 12-47), 35.0 (IQR, 20-88) and 60.0 (IQR, 23-110) for academia/non-profit CTs. This enrollment difference between sponsor types was significant ($p < 0.05$) in phases 2 and 2/3. The mean enrollment was approximately 96% (industry) and 83% (academia/non-profit) higher than the median. Of the 73,071 participants enrolled in industry-funded trials, 59.4% had been recruited for phase 3 CTs, followed by 33.6% for phase 2 CTs, and 6.9% for phase 2/3 CTs. Academia/non-profit enrolled 44.0% of 24,959 participants in phase 3 CTs, 40.7% in phase 2 CTs, and 15.3% in phase 2/3 CTs. In analyzing gender eligibility of RD CTs, we found that the majority of the studies, 89.3%, admitted participants of any gender, whereas 7.1% and 3.6% of RD CTs enrolled only male and female

subjects, respectively. In sum, industry-led trials consistently enrolled consistently more patients than academia/non-profit-funded trials, with notable variability as reflected by the standard deviation in enrollment.

Participant Age

A RD can affect anyone irrespective of age, but at least half of RDs manifest themselves in early childhood. To determine if this is reflected in RD CTs, the participant age was assessed. Therefore, the entries for the ClinicalTrials.gov categories “participant age”, “participant minimum age” and “participant maximum age” were retrieved (**Table 3**).

Participant Minimum Age	n (%)	Participant Maximum Age	n (%)
< 1 year	24 (2.5)	< 1 year	15 (2.5)
1-10 years	204 (20.8)	1-10 years	31 (5.2)
11-18 years	637 (64.9)	11-18 years	90 (15.2)
19-35 years	66 (6.7)	19-35 years	47 (7.9)
36-65 years	50 (5.1)	36-65 years	164 (27.6)
65<	0 (0.0)	65<	247 (41.6)
Total	981 (100)	Total	594 (100)

Table 3. Participant minimum and maximum age as indicated by RD CTs in our dataset (n=1056).

A minimum age for participants was entered for 92.9% (n=981). Of the CTs showing a minimum age, 88.2% allowed patients under 18 years to be enrolled. In contrast, only 56.3% of the studies indicated an upper age limit for participants. Of those, 41.6% indicated an extended age of eligibility above 65 years and a notable fraction (15.2%) of trials set the maximum age between 11 and 18 years. While extracting the minimum and maximum age limits was straightforward, the analysis of the participant age, filled out by 96.8% of the studies, proved complicated due to the lack of uniformity of the information entered. After manual categorization into age groups, we were able to visualize the data (**Fig. 2**). Even though around three quarters of the studies set the upper age limit to more than 60 years,

269 numerous studies put their focus on a younger population, mirrored by the high proportion of
270 studies indicating a minimum participant age below 18.

271

272 **Figure 2.** Graphic representation of age restrictions for participants of the RD CTs in our dataset. Of
273 the total of 1,056 CTs that were analyzed, 1,022 entered age specifications.

274 Study duration

275 Another aspect of CTs is study duration, as calculated in this analysis from the study start to
276 the study completion date. We found that phase 2 studies conducted by industry were, with a
277 median duration of 22 months (IQR, 14-33), significantly ($p < 0.0001$) shorter than their
278 academia/non-profit-led equivalent, with a median duration of 33 months (IQR, 22-47)(**Fig.**
279 **3**). This trend could be similarly observed in phase 3 CTs, with industry conducting shorter
280 studies with a median of 27 months (IQR, 18-41) versus 34.5 months (IQR, 19-52) for
281 academia/non-profit CTs ($p < 0.05$). In contrast, the study duration did not differ significantly
282 in phase 2/3 CTs between industry and academia/non-profit with a median of 29 (IQR, 21-
283 37) and 31 (IQR, 18-48), respectively. In summary, industry-funded phase 2 and 3 RD CTs
284 are of a shorter duration than studies led by academia/non-profit.

Figure 3. Comparison of study duration in months between industry- and academia/non-profit-sponsored RD CTs. This analysis is based on the dataset comprising 1,056 studies.

Result reporting among rare disease clinical trials

In 2007, the FDAAA was introduced requiring the posting of results for eligible studies on ClinicalTrials.gov within twelve months after study completion (FDAAA section 801). A CT qualifies as eligible or applicable to the FDAAA if the drug, biological or device under investigation has been manufactured in the U.S. or its territories, or if the CT has at least one study site in the U.S. or its territories. To examine result reporting, a second dataset of (n=725 CTs) consisting of 55.9% phase 2, 7.6% phase 2/3, and 36.6% phase 3 CTs was generated (**Supplementary table 1**). Overall, 44.8% (n=325) trials had entered results while

55.2% (n=400) had not. Of those that failed to report results, 65.8% were phase 2, 9.8% were phase 2/3, and 24.5% were phase 3 CTs. Industry reported consistently more results over all years (2008-2015) with a total of 56.3% (n=243) reporting RD CTs. Strikingly, only 28.0% (n=82) of studies conducted by academia/non-profit did likewise. To explore if sponsors in the non-reporting dataset were meeting their obligations under the regulations, we extracted the RD CTs which were identified as including at least one U.S. site (n=134) or using a drug manufactured within the U.S. (n=1). For the remainder of the studies (n=265) determining if the FDAAA was applicable could not be easily concluded from the information included in ClinicalTrials.gov, thus a random sample of approximately 25% (n=67) were examined manually. The majority (n=53, 79.1%) of the studies in this sample were not applicable to the FDAAA, while four (6%) CTs were identified as applicable. The remaining ten (14.9%) studies in this sample did not provide enough information for a clear categorization. We found that one of the studies that was not applicable displayed the status “results submitted” with no results entered in the respective entry field meaning that the results might currently be under evaluation. Extrapolating the manually extracted dataset of 67 studies to the results of the overall number of non-reporting trials, we estimated that 20.8% of the included 725 CTs failed to report results although required by U.S. law. Thereof, 105 CTs (24.3%) are industry-funded and 46 CTs (15.7%) academia/non-profit-funded studies. Adding trials with unclear applicability (0.9% industry- and 12.3% academia/non-profit-led CTs), the overall proportion of result non-reporting CTs, although (potentially) legally required, increases to 25.2% and 28.0% for studies initiated by industry and academia/non-profit, respectively. In summary, more than half of the industry-funded and roughly one third of academia/non-profit-funded RD CTs report results online after study completion. Of those that unambiguously fall under the regulation of the FDAAA, CTs sponsored by academia/non-profit enter results more often than industry-led CTs, with the latter posting more results

online on a voluntary basis. However, including also potentially applicable CTs, result reporting practices do not differ between sponsors.

DISCUSSION

We conducted a landscape analysis of completed phase 2, 2/3 and 3 RD CTs registered in the ClinicalTrials.gov database, including CTs from all disease areas except oncology and infectious diseases. RD CTs were shown to be mostly sponsored by industry, which is in line with previous findings in more common diseases¹². Academia/non-profit CTs prevail in phase 2/3 possibly because CTs in this phase often explore already approved drugs in new populations, or for extended indications. This falls in line with a previous observation of academia-led trials peaking predominantly before phase 3¹³. The present industry dominance in phase 3 CTs, which often are needed for regulatory approval, can be linked to those trials characteristically being large and of longer duration rendering them costly. Similar to previous reports, drug interventions represent the most frequent type of intervention in our dataset¹⁴. Unsurprisingly, industry focused on drugs and biologicals in all phases, with biologicals more common in phase 2/3. Academia/non-profit, although similarly focused on drugs, explored a broader array of interventions, including devices and dietary supplements. That might be partially due to the challenges posed by the nature and diversity of the dietary supplements branch and its globally varying regulations among different jurisdictions or governmental dominance in this field¹⁵. The strong presence of academia/non-profit sponsors in CTs around biologicals and drugs could be due to research done on approved drugs aiming to extend their scope towards new applications or patient groups in RDs. As previously reviewed¹⁶, pharmaceutical companies and academics are entering into collaborations to repurpose approved or discontinued drugs for other indications, including RDs. This may explain the increased numbers of non-industry sponsored phase 2/3 trials. Overall, comparing

our data with similar data in ClinicalTrials.gov, no differences between our RD dataset and the CTs in more common diseases could be detected and intervention types employed in RD research, with the largest group being phase 2 CTs investigating drugs conducted by industry, reflect the common practice in general clinical research¹⁷.

Most RD CTs are genetic or neurologic diseases. The high prevalence of genetic CTs in the RD dataset is to be expected, as the majority of RDs are thought to be genetic in origin¹⁸. Among these, CF is the most researched disease, representing also the most common genetic disease in Caucasian children counting 70,000 cases worldwide. This substantial number of patients, paired with early screening policies and a molecular understanding of the disease facilitates the setup of CT and thereby therapy development¹⁹⁻²⁰, leading pharmaceutical companies to conduct studies in this field²¹. Similar reasons might apply for neurologic disorders, the second focus of CTs in our dataset, which occur relatively frequently in the pediatric population²². These observations are in line with what can be found for common diseases present in ClinicalTrials.gov, where nervous system disorders are the most researched disease area, followed by neoplasms and general pathologies. In contrast, digestive system diseases, heart and blood diseases, and behaviors and mental disorders were highly represented in ClinicalTrials.gov, but not in our RD dataset. Therefore, although rare diseases are numerous, the vast majority of clinical trials focus on a few disease categories and conditions, such as CF. Furthermore, we found Huntington disease (HD) representing the top disease in rare eye disorders, followed by uveitis. Although HD is not primarily an eye disorder, a possible explanation for this finding could be a common endpoint in this disease (Unified Huntington's Disease Rating Scale), including ocular assessments causing its misclassification as eye disorder. This example highlights the difficulties that can occur when analyzing data from Clinicaltrials.gov that has not been curated or reviewed critically.

In line with a recently published study²³, we identified North America and Europe as the regions and the U.S. and Germany as the countries with the most study locations. The high proportion of U.S.-led CTs could be explained by the strong presence of the pharma industry compared to other countries with the ensuing availability of financial and infrastructural resources as well as the strong presence of active patient associations and foundations that play a key role in advancing research²¹. Japan, Australia, Argentina and South Africa were the countries with most CTs in Asia, the Oceania region, Middle and South America and Africa, respectively. However, 40.2% of CTs did not report a location, biasing the data and its interpretation. In accordance with a previous report analyzing the International Clinical Trial Registry Platform (ICTRP), we found Japan to be the country with the most CT sites in Asia²³. While the mentioned report attributes the shift away from “traditional” CT sites in Western countries to lower study costs in other countries, the study location for RD CTs could be more influenced by patient prevalence, the availability of specialized care centers and specific legislation fostering RD research²⁴⁻²⁵.

Considering the general scarceness of patients and experts/specialized care centers in RDs, it is not surprising that half of the trials indicate at most five sites. In contrast, almost two thirds of the trials indicated more than one study site, pointing towards the implementation of more, but smaller study sites in RD research. Interventional RD CTs that were previously found to have less study sites compared to non-RDs might provide support for this hypothesis²⁶. The correlation we found between industry-funded CTs and an increased number of study sites could be linked to the different financial support received compared to academia/non-profit.

Although phase 2 CTs prevail in our dataset, most participants were enrolled in phase 3 CTs, with the majority enrolled in industry sponsored CTs. A study analyzing common disease CTs of all phases reported an overall enrollment rate below 100 participants for 62% of studies, which was the same percentage we observed in phase 3 CTs in ClinicalTrials.gov.

Examining phase 2 and 2/3 RD CTs, the proportion of studies enrolling 100 or less patients rose to 87.8% and 72.8%, respectively. Comparing our dataset to the aforementioned study based on the respective median enrollment, we found comparable accrual numbers between RD CTs overall and therein described oncology trials, whilst mental health and cardiovascular CTs were higher at 85 and 100, respectively. It is somewhat surprising that the number of patients in RD CTs and non-RD CTs are similar, as we expected RD CTs to enroll fewer patients as previously indicated in a study comparing rare with non-rare disease CTs²⁶. While this study describes mostly early phase CTs with fewer participants, most of the patients in our dataset were enrolled in phase 3 CTs. Additionally, the limited power of small studies to show significant clinical efficacy, might be avoided by study sponsors resulting in higher accrual numbers. Reasons for less participant accrual in non-RD CTs could be competing trials targeting similar participant populations or even an increased focus on small sub-populations within a larger disease area. This indicates that CTs in RDs and more common diseases may be becoming more similar and both may have issues with recruitment of sufficient numbers of patients to draw firm conclusions. Notably, we observed great heterogeneity between trials enrolling few patients, sometimes in single digits and trials enrolling hundreds or thousands, a phenomenon that has also been previously reported¹⁷. Gender disparity in biomedical research, which may insert a bias in clinical findings and therefore may lead to a disadvantage in clinical practice for women, is recognized and has been described before^{17,27,28,29}. Although we did not observe a significant gender bias in RD CTs, we found that out of all studies recruiting only patients from a specific gender, twice as many recruited only male patients than female, which could be partially attributed to the aforementioned historic and general underrepresentation of women in CTs. The age of eligibility for study subjects is crucial in many diseases, often influencing the overall study success. The majority of RDs are thought to be genetic disorders, which present

already in early childhood or adolescence, thereby necessitating an early therapy start^{30–32}.
 Consequently, RD CTs had a wide age range with the majority including pediatric patients,
 unlike in more common diseases that can occur throughout life^{17,26}.
 CT participation is often associated with great efforts by (pediatric) patients and their family
 members, thus the study duration can have a major impact on participant compliance and
 retention in the study. We found a direct correlation between the study duration and study
 phase, which is in line with common clinical research practices such as monitoring
 procedures, larger sample sizes, time to analyze larger datasets including side effects etc. in
 phase 3 studies. The fact that industry-funded CTs are significantly shorter than academia-
 /non-profit-led CTs could be attributed to the former usually having more resources, which
 allows for more sites, thereby increasing patient recruitment velocity. Comparing RD CTs to
 all phases of nephrology or cardiology studies, no significant difference could be detected in
 the overall study duration¹⁴.
 Clinical research is essential for clinical decision making and providing the best standard of
 care for patients. Since the enactment of the FDAAA in 2007, CT result reporting is no
 longer only ethically desirable, but also mandatory within twelve months upon trial
 completion. However, this rule only applies to studies investigating a drug, biological or
 device manufactured in the U.S. or studies indicating at least one study site in the U.S. or
 within its territories⁶. Our analysis of studies completed before 2015 showed that after at least
 two years following completion less than half of all analyzed RD CTs posted results on
 ClinicalTrial.gov. A previous study on result reporting under FDAAA regulations found that
 only 22% of the CTs report results timely, with only 10% doing so on a voluntary basis.
 Additionally, the authors stated that result reporting occurs in only 40% of industry-funded
 and 9% not solely industry-funded CTs with phase 3 studies being the most frequently
 reported CTs⁷. Despite opposition of the FDA³³, an unofficial analysis conducted by the U.S.

National Institutes of Health (NIH) confirms that industry performs better than public sponsors (NIH and NIH-funded), when it comes to timely result reporting, with 52% vs. 35%, respectively³⁴. A recent study analyzing the availability of phase 3 and 4 RD CT results on ClinicalTrial.gov found that 68% of the trials affected by the FDAAA reported results³⁵. In our dataset, phase 2 trials account for roughly two thirds of the non-reporting CTs we identified. Studies registered with the EU Clinical Trials Register (EUCTR), which requires result disclosure within 12 months after trial completion, performed similarly, with only half of the applicable CTs posting results³⁶. This recent report also found that CT result reporting was linked to later study phases and industry funding. Drawing a final conclusion on the result reporting rate between the two sponsor categories in our dataset is not obvious due to the incompleteness of the information provided online. Considering only studies that clearly apply to the FDAAA, industry funding is shown to be associated with a higher degree of non-reporting in RD CTs. However, including potentially applicable CTs, academia/non-profit and industry fall abreast. This importantly highlights the need for complete information in order for external parties to be able to draw transparent conclusions. Generally, industry trials in RDs were associated with better overall result posting even when not required by the FDAAA, potentially due to more strictly regulated and overseen follow-up processes and the fact that industry-funded trials tend to be larger and larger studies are more likely to be published³⁷.

The finding that RD CTs adhere more strictly to the FDAAA than CTs overall might be due to ethical obligations towards these patients and the high value of clinical data from a CT, which may be the only one performed in a patient population. RD CTs also include many pediatric patients and pediatric CTs were found more likely to be completed³⁸. Regardless of the reasons, it is encouraging to note that RD CTs are reported at a higher rate than other CTs. Ultimately, CTs need to overcome the widely recognized and general deficit of

consistent and transparent data sharing practices, not only to improve patient care, but also to value the participants who help advancing science and future patients.

CONCLUSION

This study provides insight into the landscape of RD CTs. RD clinical research tends to be industry-funded and focused on treatments with drugs or biologicals and many trials involve a relatively small number of participants and patients starting from very early in life. Generally, industry funding has been associated with larger studies, including larger numbers of participants and more study sites, but slightly shorter study duration compared with academia/non-profit trials. Finally, CT results in rare diseases are being made often publicly available more frequently than has been reported for studies entered in ClinicalTrial.gov, but improvements are still needed to make all data readily available to the public.

Limitations

There are some limitations in this study to be taken into consideration. First, ClinicalTrials.gov does not cover all trials conducted worldwide. However, there is a reported 80% overlap between ClinicalTrials.gov and the WHO ICTRP portal¹⁸. Secondly, there is no single standard ontology for the description of clinical research and, despite extensive manual data curation efforts, the dataset may still contain misclassified studies. Conversely, some CTs may have been excluded from our study, due to the disease under study not conforming to the ORDO naming convention. Efforts were made to identify, correct or remove erroneous or ambiguous as well as carelessly entered data prior to analysis, however, an element of uncertainty remains. Additionally, a notable fraction of studies may provide divergent information on ClinicalTrials.gov and EUCTR, making comparisons difficult³⁹. Although the FDAAA was introduced to increase transparency, this legislation came with certain

limitations; For example, its applicability to studies with at least one study site or an item manufactured in the U.S. or U.S. territories. It is, however, not evident which studies are applicable and which ones are exempt. Even though we attempted to address this limitation by examining a random sample of 25% of the trials manually, errors may still be present. In this study, early proof-of-concept trials, which can be impactful on the scientific community, e.g. in order to avoid duplicity of resources, are not reviewed. Finally, this study represents a snapshot of RD CTs as they were entered in March 2018 and some study details may have been added after we retrieved the data.

REFERENCES

1. de Vruet R, Baekelandt ERF, de Haan JMH. Priority Medicines for Europe and the World “A Public Health Approach to Innovation” Update on 2004 Background Paper Background Paper 6.19 Rare Diseases. 2013.
2. Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. *Nat Rev Genet.* 2013; 3;14:681.
3. Global Genes. RARE Facts. 2018. <https://globalgenes.org/rare-facts/>. Accessed 6 Nov 2018.
4. Food and Drug Administration. Orphan Drug Act - Relevant Excerpts. 2013. <https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-act-relevant-excerpts>. Accessed 7 Nov 2018.
5. Food and Drug Administration. Orphan Drug Designations and Approvals. 1983. <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/>. Accessed 7 Nov 2018.
6. U.S. Public Law 110-85; Section 801. Food and Drug Administration Amendments

-
- 520 Act (FDAAA) of 2007. 2007.
- 521 7. Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical
522 trial results on ClinicalTrials.gov: cross sectional study. *BMJ*. 2012;344:d7373.
- 523 8. Riveros C, Dechartres A, Perrodeau E, Haneef R, Boutron I, Ravaud P. Timing and
524 Completeness of Trial Results Posted at ClinicalTrials.gov and Published in Journals.
525 *PLOS Med*. 2013;10:e1001566.
- 526 9. Powell-Smith A, Goldacre B. The TrialsTracker: Automated ongoing monitoring of
527 failure to share clinical trial results by all major companies and research institutions.
528 *F1000Research*. 2016;5:2629.
- 529 10. U.S. National Library of Medicine. ClinicalTrials.gov - Glossary. 2018.
530 <https://clinicaltrials.gov/ct2/about-studies/glossary>. Accessed 11 Nov 2018.
- 531 11. U.S. National Library of Medicine. ClinicalTrials.gov - Trends. 2018.
532 <https://clinicaltrials.gov/ct2/resources/trends>. Accessed 11 Nov 2018.
- 533 12. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM.
534 Compliance with Results Reporting at ClinicalTrials.gov. *N Engl J Med*. 2015;
535 11;372:1031–9.
- 536 13. Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, et al. Publication and
537 reporting of clinical trial results: cross sectional analysis across academic medical
538 centers. *BMJ*. 2016;352:i637
- 539 14. Inrig JK, Califf RM, Tasneem A, Vegunta RK, Molina C, Stanifer JW, et al. The
540 landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov.
541 *Am J Kidney Dis*. 2014;63:771–80.
- 542 15. Dwyer JT, Coates PM, Smith MJ. Dietary Supplements: Regulatory Challenges and
543 Research Resources. *Nutrients*. 2018;10:41.
- 544 16. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug

-
- 545 repurposing: progress, challenges and recommendations. *Nat Rev Drug Discov.*
546 2018;18:41.
- 547 17. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A.
548 Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010. *JAMA.*
549 2012;307:1838–47.
- 550 18. EURORDIS Rare Diseases Europe. About Rare Diseases. 2015.
551 <https://www.eurordis.org/about-rare-diseases>. Accessed 6 Nov 2018.
- 552 19. Mayer-Hamblett N, Boyle M, VanDevanter D. Advancing clinical development
553 pathways for new CFTR modulators in cystic fibrosis. *Thorax.* 2016;71:454-461.
- 554 20. Bell SC, De Boeck K, Amaral MD. New pharmacological approaches for cystic
555 fibrosis: Promises, progress, pitfalls. *Pharmacol Ther.* 2015;145:19–34.
- 556 21. Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, Retsch-Bogart G, et al.
557 Progress in cystic fibrosis and the CF Therapeutics Development Network. *Thorax.*
558 2012;67:882–90.
- 559 22. Huang Y, Yu S, Wu Z, Tang B. Genetics of hereditary neurological disorders in
560 children. *Transl Pediatr.* 2014;3:108–19.
- 561 23. Jeong S, Sohn M, Kim JH, Ko M, Seo H-W, Song Y-K, et al. Current globalization of
562 drug interventional clinical trials: characteristics and associated factors, 2011-2013.
563 *Trials.* 2017;18:288.
- 564 24. Aymé S. RC. 2012 Report on the State of the Art of Rare Disease Activities in Europe
565 of the European Union Committee of Experts on Rare Diseases.
- 566 25. Tsukamoto K, Carroll KA, Onishi T, Matsumaru N, Brasseur D, Nakamura H.
567 Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks.
568 *Clin Ther.* 2016;38:574–81.
- 569 26. Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus

Mair *et al.* Characteristics and data reporting in rare disease clinical trials

- 570 non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014 Nov
- 571 26;9:170.
- 572 27. Hamberg K. Gender bias in medicine. Womens Health (Lond.). 2008;4:237–43.
- 573 28. Ramasubbu K, Gurm H, Litaker D. Gender Bias in Clinical Trials: Do Double
- 574 Standards Still Apply? J Womens Health Gend Based Med. 2001;10:757–64.
- 575 29. Choi EK, Kim MJ, Lim NK, Park HY. Review of the Registration in the Clinical
- 576 Research Information Service. J Korean Med Sci. 2016;31:1–8.
- 577 30. Jimenez-Sanchez G, Childs B, Valle D. Human disease genes. Nature. 2001;409:853–
- 578 5.
- 579 31. McClellan J, King M-C. Genetic Heterogeneity in Human Disease. Cell.
- 580 2010;141:210–7.
- 581 32. Yum K, Wang ET, Kalsotra A. Myotonic dystrophy: disease repeat range, penetrance,
- 582 age of onset, and relationship between repeat size and phenotypes. Curr Opin Genet
- 583 Dev. 2017;44:30–7.
- 584 33. Hawkes N. FDA disagrees with BMJ study that found clinical trials were not being
- 585 reported. BMJ. 2012;344:e3277.
- 586 34. Marin Dos Santos DH, Atallah ÁN. FDAAA legislation is working, but
- 587 methodological flaws undermine the reliability of clinical trials: a cross-sectional
- 588 study. PeerJ. 2015;3:e1015.
- 589 35. Dechartres A, Riveros C, Harroch M, Faber T, Ravaud P. Characteristics and Public
- 590 Availability of Results of Clinical Trials on Rare Diseases Registered at
- 591 Clinicaltrials.gov. JAMA Intern Med. 2016;176:556–8.
- 592 36. Goldacre B, DeVito NJ, Heneghan C, Irving F, Bacon S, Fleminger J, et al.
- 593 Compliance with requirement to report results on the EU Clinical Trials Register:
- 594 cohort study and web resource. BMJ. 2018;362:k3218.

37. Brænd AM, Straand J, Jakobsen RB, Klovning A. Publication and non-publication of drug trial results: a 10-year cohort of trials in Norwegian general practice. *BMJ Open*. 2016;6:e010535.
38. Dufetelle E, 't Jong GW, Kaguelidou F. Randomized controlled trials in pediatric inpatients had higher completion rates than adult trials: a cross-sectional study. *J Clin Epidemiol*. 2018;100:53–60.
39. Fleming J, Goldacre B. Prevalence of clinical trial status discrepancies: A cross-sectional study of 10,492 trials registered on both ClinicalTrials.gov and the European Union Clinical Trials Register. *PLoS One*. 2018;13:e0193088.

SUPPLEMENTARY MATERIAL

Result reporting per Study Start Year and Study Phase (n=725)

Study Start Year	Overall, n (%)	Phase 2, n (%)	Phase 2/3, n (%)	Phase 3, n (%)
2008	70 (49.3)	28 (19.7)	4 (2.8)	38 (26.8)
2009	54 (42.9)	23 (18.3)	1 (0.8)	30 (23.8)
2010	57 (48.3)	25 (21.2)	2 (1.7)	30 (25.4)
2011	54 (45.0)	22 (18.3)	4 (3.3)	28 (23.3)
2012	42 (40.8)	20 (19.4)	3 (2.9)	19 (18.4)
2013	36 (48.6)	18 (24.3)	2 (2.7)	16 (21.6)
2014	9 (25.0)	4 (11.1)	0 (0.0)	5 (13.9)
2015	3 (42.9)	2 (28.6)	0 (0.0)	1 (14.3)

Result non-reporting per Year and Study Phase (n=725)

Study Start Year	Overall, n (%)	Phase 2, n (%)	Phase 2/3, n (%)	Phase 3, n (%)
2008	72 (50.7)	49 (34.5)	6 (4.7)	17 (12.0)
2009	72 (57.1)	44 (34.9)	10 (7.9)	18 (14.3)
2010	60 (51.3)	36 (30.8)	7 (6.0)	17 (14.5)
2011	66 (55.0)	48 (40.0)	6 (5.0)	12 (10.0)
2012	61 (59.2)	39 (37.9)	5 (4.9)	17 (16.5)
2013	38 (51.4)	27 (36.5)	1 (1.4)	10 (13.5)
2014	27 (75.0)	18 (50.0)	3 (8.3)	6 (16.7)
2015	4 (57.1)	2 (28.6)	1 (14.3)	1 (14.3)

Result reporting per Study Start Year and Sponsor (n=725)

Study Start Year	Overall, n (%)	Industry, n (%)	Academia/ Non-Profit, n (%)
2008	70 (49.3)	49 (34.5)	21 (14.8)
2009	54 (42.9)	41 (32.5)	13 (10.3)
2010	57 (48.7)	40 (34.2)	17 (14.5)

Mair *et al.*

Characteristics and data reporting in rare disease clinical trials

2011	54 (45.0)	43 (35.8)	11 (9.2)
2012	44 (42.7)	33 (32.0)	11 (10.7)
2013	36 (48.6)	29 (39.2)	7 (9.5)
2014	9 (25.0)	8 (22.2)	1 (2.8)
2015	3 (42.9)	2 (28.6)	1 (14.3)

Result non-reporting per Study Start Year and Sponsor (n=725)

Study Start Year	Overall, n (%)	Industry, n (%)	Academia/ Non-Profit, n (%)
2008	72 (50.7)	33 (22.8)	39 (28.2)
2009	72 (57.1)	35 (28.0)	37 (28.8)
2010	60 (51.3)	31 (25.6)	30 (25.6)
2011	66 (55.0)	28 (23.4)	38 (32.3)
2012	59 (55.0)	25 (24.5)	34 (32.1)
2013	38 (57.3)	21 (29.3)	17 (22.7)
2014	27 (75.0)	14 (38.9)	13 (36.1)
2015	4 (57.1)	1 (14.3)	3 (42.9)

Supplementary table 1. Clinical trial result publication/non-publication per study start year and sponsor irrespective the eligibility of the specific study.

DECLARATIONS

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The general datasets generated and analyzed during the current study are available in the ClinicalTrials.gov repository, <https://clinicaltrials.gov/>. Moreover, the specific datasets used and analyzed during the current study are available from Timothy J. Seabrook (timothy_j.seabrook@roche.com) on reasonable request.

Competing interests

NKM was employed at F. Hoffmann-La Roche Ltd at the time of study conception, data collection and analysis. JG, RRE, and TJS are employees of and hold shares in F. Hoffmann-La Roche Ltd. We attest that we herein have disclosed any and all financial or other

relationships that could be construed as a conflict of interest and that all sources of financial support for this study have been disclosed.

Funding

This research was supported by F. Hoffmann-La Roche Ltd. The funding body was not part of the study design, data collection, analysis, and interpretation, or in writing the manuscript.

Authors' contributions

The study was conceived by JG, RRE, and TJS. Data acquisition, curation and analysis were performed by NKM. The results were interpreted by all authors. The manuscript was compiled by NKM and revised by JG, RRE, and TJS. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Dr. Winnie Yeung for advice and assistance with the statistical analysis.

Footnotes

Not applicable.